Valley Fever (Coccidioidomycosis)
Valley Fever (Coccidioidomycosis)
References
- Pathogen Safety Data Sheets: Infectious Substances – Coccidioides spp. — Public Health Agency of Canada. Government of Canada, Public Health Agency of Canada, updated November 2010
- Clinical Overview of Valley Fever — Centers for Disease Control and Prevention, Fungal Diseases. CDC, For Health Care Providers, updated January 31, 2025
- For health professionals: Valley fever (coccidioidomycosis) — Public Health Agency of Canada. Government of Canada, Public Health Agency of Canada
- 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis — Infectious Diseases Society of America (Galgiani JN, Ampel NM, Blair JE, et al.). Clin Infect Dis 2016;63(6):e112-e146
- Coccidioidomycosis in Pregnancy: Case Report and Review of the Literature — The American Journal of Medicine (Crum NF, Ballon-Landa G). Am J Med 2006;119(11):993.e11-993.e17
Clinical Snapshot
Coccidioides is a dimorphic fungus that lives in soil as branching hyphae and releases small, thick-walled, aerosolizable arthroconidia (2-5 μm) whenever contaminated soil is disturbed. Once inhaled, each arthroconidium transforms into a spherule — a large (up to 120 μm) structure that fills with 200-300 endospores, each able to rupture out and form a new spherule, propagating infection within tissue.[1] Two essentially indistinguishable species cause disease: C. immitis (concentrated in California) and C. posadasii (the rest of the endemic range); there is no clinically meaningful difference between them.[2]
This is a US-endemic disease, not a Canadian one. Highly endemic in southern Arizona and California's San Joaquin ("Central") Valley, with a broader range across California, Nevada, New Mexico, Texas, Utah, south-central Washington State, northern Mexico, and Central/South America.[2][3] No autochthonous transmission occurs in Canada — a Canadian clinician will encounter this almost exclusively in returning travellers, seasonal "snowbird" residents of the US Southwest, and, rarely, solid-organ recipients from a donor with occult infection.[2]
The spectrum of disease
Roughly 60% of infections are asymptomatic.[2] Most of the rest develop a self-limited illness resembling community-acquired pneumonia — fever, dry cough, dyspnea, fatigue, headache, night sweats, myalgias/arthralgias, sometimes a rash — typically appearing 1-3 weeks after exposure and resolving without antifungal treatment.[2][1] A genuinely useful, classically recognized clue is fever, arthralgias (knees/ankles), and either erythema nodosum or erythema multiforme — historically "desert rheumatism."[1] Approximately 5-10% of symptomatic patients fail to fully recover and develop complications or chronic pulmonary disease (persistent nodules, cavities, chronic fibrocavitary pneumonia); disseminated disease (skin, soft tissue, bone/joint, or meninges) occurs in an estimated 1% overall, but at meaningfully higher rates in specific risk groups.[2]
Most immunocompetent patients with uncomplicated pulmonary disease do not need antifungal treatment. No randomized trial evidence shows treatment shortens illness or prevents complications in uncomplicated disease. Treatment is reserved for patients who are immunosuppressed, pregnant, diabetic, of higher-risk ancestry (African or Filipino), severely ill, or have disseminated disease — see Choose Initial Treatment.[2]
Recognize the Condition
Incubation and timing
Symptoms, when they occur, typically appear 1-3 weeks after exposure — which may be well after a traveller has returned home to Canada, making the travel-history link easy to miss if not specifically asked about.[2][1]
Primary pulmonary disease ("Valley fever")
The dominant presentation is an atypical, community-acquired-pneumonia-like illness: fever, nonproductive cough, dyspnea, pleuritic chest pain, fatigue, headache, night sweats, myalgias/arthralgias.[2] A maculopapular rash occurs in a meaningful minority, and the combination of fever, arthralgias, and either erythema nodosum or erythema multiforme ("desert rheumatism") is a recognizable, diagnostically useful pattern, more common in women.[1] Chest imaging may show an infiltrate, hilar/mediastinal adenopathy, or a pleural effusion — none distinguishes Valley fever from bacterial CAP on imaging alone.[2] Atypical pneumonia not improving on standard antibacterial therapy, especially with a compatible travel history, should prompt specific testing — Coccidioides is a fungus and does not respond to antibacterial agents.[2]
Pulmonary nodules and cavities
A chronic pulmonary nodule ("coccidioidoma") can persist after primary infection, often asymptomatic and discovered incidentally — frequently mistaken initially for malignancy or tuberculosis. A minority develop a thin-walled cavity, which may be asymptomatic or cause hemoptysis, chest pain, or secondary bacterial infection.[2]
Disseminated disease
Disseminated disease occurs in an estimated 1% of infections overall, but at substantially higher rates in specific risk groups (see Risk Factors). It most commonly affects skin (verrucous/granulomatous plaques, abscesses, draining sinus tracts), bones/joints (osteomyelitis, septic arthritis), and, most seriously, the meninges.[2]
Coccidioidal meningitis is the most feared complication. It may occur in 30-50% of disseminated infections and is essentially always fatal without treatment. It can present subacutely — headache, nausea, vomiting, altered mental status, sometimes with only low-grade or absent fever — without a clearly remembered preceding respiratory illness, so it should be considered in any patient with a compatible neurologic presentation and an endemic-area travel history, however remote.[1]
Post-Valley fever fatigue and children
Some patients experience a prolonged fatigue syndrome after apparently resolved primary disease — a diagnosis of exclusion once ongoing organ involvement has been reasonably ruled out. Children generally have milder illness than adults, though the same spectrum can occur.
Risk Factors
Exposure risk (acquiring infection)
- Living in, or travelling/residing seasonally in, an endemic area — for Canadians, overwhelmingly southern Arizona or California's San Joaquin Valley, but also elsewhere in the US Southwest, south-central Washington State, northern Mexico, or Central/South America.[2][3]
- Occupations and activities that disturb dust and soil in an endemic area: construction, agricultural work, archaeology or excavation, military field training.[2]
- Outdoor recreational and hobby activities in an endemic area: gardening and landscaping, dirt biking and off-road recreation, hiking, and golf — genuinely relevant to Canadian retirees wintering in Arizona golf and retirement communities.[2]
- Large-scale soil-disruption events in an endemic area, such as dust storms or earthquakes, which can aerosolize spores over a wide area.[2]
- Rarely, solid-organ transplantation from a donor with occult infection (donor-derived coccidioidomycosis), or fomite transmission — both very uncommon.[3]
Risk factors for severe or disseminated disease (these should trigger treatment, not just observation)
- African-American race or Filipino ethnicity — both are independently associated with a substantially higher risk of dissemination; Hispanic ethnicity carries an intermediate increased risk.[2][4]
- Pregnancy, particularly the third trimester or the immediate postpartum period — dissemination risk rises sharply as pregnancy progresses (see Special Populations).[2][5]
- Immunosuppression: HIV/AIDS, solid organ transplantation, high-dose corticosteroid therapy, and anti-tumour necrosis factor (TNF) biologic therapy.[2]
- Diabetes mellitus.[2]
- Primary infection during infancy, and age greater than 55 years.[4]
- Chronic debilitation or significant underlying disease, including pre-existing cardiopulmonary disease.[4]
- A high inoculum exposure (e.g., an occupational or dust-storm exposure involving a large amount of disturbed contaminated soil).[4]
Red Flags & Refer
Any of the following warrants urgent escalation — hospitalization, infectious diseases consultation, or both:
- Headache with nausea/vomiting, altered mental status, or any other neurologic finding in a patient with a compatible endemic-area exposure history, at any interval after that exposure — evaluate urgently for coccidioidal meningitis, which is fatal without treatment.[1]
- A pregnant patient with confirmed or suspected coccidioidomycosis, especially in the second or third trimester — refer for infectious diseases and high-risk obstetric input given the sharply rising risk of dissemination as pregnancy progresses.[5]
- New bone or joint pain and swelling, or a non-healing skin lesion/draining sinus, in a patient with any history (even remote) of a compatible respiratory illness and endemic-area travel — evaluate for disseminated disease rather than attributing symptoms to musculoskeletal strain or a routine skin infection.[2]
- A community-acquired pneumonia that is not responding to standard antibacterial therapy in a patient with an endemic-area travel or residence history — Coccidioides does not respond to antibacterial agents, and this pattern should specifically prompt testing.[2]
- Severe illness by any of the following criteria: fever persisting more than 1 month, weight loss exceeding 10% of body weight, intense night sweats persisting more than 3 weeks, infiltrates involving more than half of one lung or portions of both lungs, prominent or persistent hilar adenopathy, an elevated complement-fixation IgG titre (≥1:16), or inability to work — these patients should be offered treatment rather than observation alone.[4]
- Any patient in a recognized high-risk group (immunosuppressed, pregnant, diabetic, of African or Filipino ancestry, or with a critical-site lesion such as vertebral involvement) diagnosed with primary pulmonary disease — route to treatment rather than watchful waiting.[2][4]
- A new pulmonary or systemic illness in a solid organ transplant recipient who has ever lived in, or received an organ from a donor associated with, an endemic area.[2]
Assessment & Diagnosis
The history is the diagnosis-enabling step — and the one most likely to be skipped
Ask specifically about travel to, or residence in, the southwestern United States, northern Mexico, or Central/South America — including brief trips and exposure weeks to months before symptom onset. Because coccidioidomycosis does not occur autochthonously in Canada, a clinician unfamiliar with it can easily miss the diagnosis simply by not asking; the illness itself offers few reliable clues without this history.[2][3]
Serologic testing
Serology is the primary diagnostic method. Enzyme immunoassay (EIA, IgM/IgG) is typically the initial screen; a positive EIA should be confirmed with immunodiffusion and complement fixation (CF) testing given EIA's meaningful false-positive rate. The CF IgG titre is also used to gauge severity and track treatment response — a rising or persistently high titre (traditionally ≥1:16, ≥1:32 notably elevated) raises concern for more severe/disseminated disease; a falling titre during treatment is reassuring.[2][4]
Other diagnostic methods
| Test | Notes |
|---|---|
| Culture | Definitive, but Coccidioides is Risk Group 3 given its extremely low infectious dose (1-10 arthroconidia) — always alert the microbiology laboratory to the clinical suspicion for safe handling.[1] |
| Histopathology | The characteristic spherule (up to 120 μm) with endospores in tissue is essentially pathognomonic.[1] |
| Urine/serum antigen | Most useful in severe/disseminated disease and immunocompromised patients with a blunted serologic response.[2] |
| Skin (delayed-hypersensitivity) testing | Not widely used in Canada; a negative test in severe illness is itself a marker of poor cell-mediated immunity and a risk factor for progression.[4] |
| PCR | Emerging, increasingly available, not yet primary.[2] |
The CDC's "Testing Algorithm for Coccidioidomycosis" provides a practical stepwise approach — a useful reference given how unfamiliar this pathway is to most Canadian prescribers.[2]
Treatment Targets
- Do not reflexively treat every diagnosed case of uncomplicated primary pulmonary coccidioidomycosis in an immunocompetent, non-pregnant adult — supportive care and structured observation is the evidence-based default for this group.
- Identify, at the time of diagnosis, any risk factor for severe or disseminated disease (immunosuppression, pregnancy, diabetes, African/Filipino ancestry, severe-illness criteria, critical-site involvement) and route these patients to treatment rather than watchful waiting.
- Use an oral azole — fluconazole or itraconazole — as first-line pharmacotherapy for most patients who do need treatment.
- Reserve amphotericin B for severe/diffuse pulmonary disease, rapidly progressive disease, disease in a critical location (e.g., the vertebral column), and coccidioidomycosis diagnosed in the first trimester of pregnancy.
- Recognize coccidioidal meningitis urgently and treat with high-dose fluconazole as first-line therapy; plan from the outset for lifelong azole suppressive therapy, since this is not a course that is ever simply completed and stopped.
- Always elicit a travel or residence history to an endemic area — this is the diagnostic step most likely to be missed by a clinician unfamiliar with a disease that does not occur domestically in Canada.
Choose Initial Treatment
No antifungal treatment is required
Because coccidioidal pneumonia resolves without treatment in the great majority of cases, and no trial evidence shows antifungal therapy shortens illness or prevents dissemination in this group, this is appropriately managed with supportive care alone — rest, hydration, antipyretics/analgesics — plus structured follow-up (see Monitoring & Follow-Up).[2]
Fluconazole 400 mg PO once daily (or itraconazole 200 mg PO 2-3 times daily) is first-line
Treatment is indicated for patients with any risk factor for severe/disseminated disease, patients meeting severity criteria (see Red Flags & Refer), and confirmed non-meningeal disseminated disease not in a critical site. Fluconazole and itraconazole have broadly comparable efficacy; itraconazole performs somewhat better for bone/joint lesions, fluconazole somewhat better for pulmonary/soft-tissue disease. Itraconazole absorption can be erratic (capsule needs an acidic environment and a high-fat meal), so serum levels are commonly checked early in prolonged therapy.[4]
| Population / severity | Regimen |
|---|---|
| Standard nonmeningeal disease | Fluconazole 400 mg PO once daily, or Itraconazole 200 mg PO 2-3 times daily |
| Severe/disseminated, not responding adequately | Fluconazole up to 800-2000 mg/day; itraconazole up to 800 mg/day, specialist-guided |
Severe, diffuse, or rapidly progressive pulmonary disease, and critical-site disease
Diffuse pulmonary disease, rapid deterioration, significant hypoxia, or disease where progression would be catastrophic (notably vertebral involvement) should be treated initially with Amphotericin B — deoxycholate (0.5-1.5 mg/kg/day IV) or a lipid formulation (2-5 mg/kg/day IV, generally better tolerated) — until clear improvement, then typically transitioned to an oral azole.[4]
Amphotericin B — azoles are avoided, especially in the first trimester
Azoles have shown teratogenicity in animal studies and are best avoided in pregnancy, specifically in the first trimester. Amphotericin B is the treatment of choice, particularly in the first trimester.[4][5] This is high-stakes: dissemination risk rises sharply with gestation — 40% before pregnancy, 50% in the first trimester, 62% in the second, and 96% in the third trimester in one review — and improved maternal/fetal survival is associated with early recognition and amphotericin B.[5]
High-dose fluconazole is first-line; once diagnosed, plan for lifelong azole suppressive therapy
Fluconazole at higher doses (400-1200 mg/day, PO or IV) is first-line for mild-moderate and even many severe cases, given excellent CSF penetration. Intrathecal/intraventricular amphotericin B (via a surgically placed Ommaya reservoir) is reserved for azole failure or intolerance, with close ID/neurosurgical involvement.[4]
Once diagnosed, azole suppressive therapy continues lifelong — not a course that is completed and stopped even after full clinical response, since relapse risk after discontinuation is high. Immunocompromised patients with any history of meningeal involvement are managed the same way.[4]